New hope for tough pancreatic cancer: personalized drug cocktail enters trials
NCT ID NCT06483555
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a low dose of erlotinib to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and effective for people with advanced pancreatic cancer. Participants are grouped by tumor type: those with 'basal-like' tumors get the new combo, while those with 'classical' tumors receive standard care. The trial aims to improve survival and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, nab-paclitaxel, and erlotinib
What this could lead to
If successful, this could lead to a more effective treatment for people with a specific type of pancreatic cancer (basal-like) that is often harder to treat.
What could go wrong
This is an early-phase trial (Phase I/II) with a small number of participants, so results may not apply to everyone. Adding erlotinib may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••